Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10637268 | 0.95 | CYP4F2 (0.54) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL18801996 | 0.86 | CYP4F2 (0.54) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL31076144 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL5561929 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL5562625 | 0.85 | CYP4F2 (0.65) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL11432813 | 0.85 | TSHR (0.52) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL1787169 | 0.83 | TSHR (0.46) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL8850863 | 0.83 | CYP4F2 (0.48) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL7718830 | 0.83 | ALDH1A1 (0.48) | CYP4F2CYP4A11TSHRALDH1A1MAPT | |
| SCHEMBL11417779 | 0.83 | ALDH1A1 (0.59) | CYP4F2CYP4A11TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-101184731-A | Indoline compounds | FOURNIER LAB SA (FR) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | CYP4F2 1271/4885CYP4A11 550/4885TSHR 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.